PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
13.25
P/E 10-15 - Fair value range. Benjamin Graham would demand a 1/3 margin of safety here. Consider Price-to-Book for asset backing.
No Data
No Data available this quarter, please select a different quarter.
43.01
P/B above 3.0 - Expensive territory. Howard Marks would require extraordinary moat evidence. Essential to verify all profitability metrics.
-69.03
Negative P/FCF indicates negative free cash flow - a classic Benjamin Graham warning sign. Verify Working Capital management and Capital Expenditure patterns.
-72.44
Negative P/OCF indicates negative operating cash flow - a classic Benjamin Graham warning sign. Verify Working Capital management and Revenue Collection efficiency.
43.01
Price above 140% of fair value - Danger zone. Philip Fisher would require extraordinary growth evidence. Scrutinize all valuation inputs carefully.
1.89%
Earnings yield below 3% - Danger zone. Philip Fisher would require extraordinary growth evidence. Examine all growth and quality metrics.
-1.45%
Negative FCF yield indicates negative free cash flow - a classic Benjamin Graham warning sign. Verify Capital Expenditure patterns and Working Capital management.